Anna D Staniszewska, Domenic Pilger, Sonja J Gill, Kunzah Jamal, Natacha Bohin, Sofia Guzzetti, Jacob Gordon, Gregory Hamm, Gill Mundin, Giuditta Illuzzi, Andy Pike, Lisa McWilliams, Gareth Maglennon, Jonathan Rose, Glen Hawthorne, Miguel Cortes Gonzalez, Christer Halldin, Peter Johnström, Magnus Schou, Susan E Critchlow, Stephen Fawell, Jeffrey W Johannes, Elisabetta Leo, Barry R Davies, Sabina Cosulich, Jann N Sarkaria, Mark J O'Connor, Petra Hamerlik
PURPOSE: We evaluated the properties and activity of AZD9574, a blood-brain barrier (BBB) penetrant selective inhibitor of PARP1 and assessed its efficacy and safety alone and in combination with temozolomide (TMZ), in preclinical models. EXPERIMENTAL DESIGN: AZD9574 was interrogated in vitro for selectivity, PARylation inhibition, PARP-DNA trapping, the ability to cross the BBB, and the potential to inhibit cancer cell proliferation. In vivo efficacy was determined using both subcutaneous as well as intracranial mouse xenograft models...
November 15, 2023: Clinical Cancer Research